½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444060

¹Ý·Áµ¿¹°¿ë ÇコÄɾî : ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Companion Animal Healthcare - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 179¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 275¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 9.03%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.

¹Ý·Áµ¿¹°¿ë ÇコÄɾî-½ÃÀå

COVID-19ÀÇ À¯ÇàÀº µ¿¹° ½ÇÇè°ú ¼öÀÇÇÐ ºñ¿ëÀ» Áõ°¡½ÃÄÑ µ¿¹° ÇコÄÉ¾î ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ÁÖ·Î Á¦Á¶ ÇöÀåÀÇ ÀϽÃÀûÀÎ Æó¼â, ¼öÃâ Á¦ÇÑ ¹× COVID-19 Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿©·¯ ±¹°¡¿¡¼­ °ø±Þ¸Á È¥¶õ°ú µ¿¹°¿ë ÀǾàÇ° ºÎÁ·ÀÌ °üÂûµÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 7¿ù CDC´Â COVID-19 ÆÒµ¥¹Í ±â°£ Áß ¹Ý·Áµ¿¹° Ä¡·á¿¡ ´ëÇÑ ±¸Ã¼ÀûÀÎ °¡À̵å¶óÀÎÀ» ¼öÀÇ»çµé¿¡°Ô ±Ç°íÇß½À´Ï´Ù. ±×·¯³ª µ¿¹° ÇコÄÉ¾î ½ÃÀå¿¡¼­ »õ·Ó°í Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇϱâ À§ÇÑ ¿¬±¸°³¹ß È°µ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 7¿ù ¸ÓÅ© µ¿¹° °Ç°­(Merck Animal Health)´Â ĵÀÚ½ºÁÖ Á¦Á¶ ½Ã¼³ÀÇ µ¿¹° ¹é½Å »ý»ê ´É·ÂÀ» ¹ÌÈ­ 1¾ï ´Þ·¯·Î µÎ ¹è·Î ´Ã·È½À´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ Áß ¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀåÀÇ ¼ºÀå¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀå¿¡ ±â¿©Çϴ ƯÁ¤ ¿äÀÎÀ¸·Î´Â ¹Ý·Áµ¿¹° ÀÔ¾ç Áõ°¡, Á¤ºÎ ¹× µ¿¹° º¹Áö °ü·Ã ³ë·Â Áõ°¡, µ¿¹° ÇコÄÉ¾î ºÐ¾ßÀÇ Ã·´Ü ±â¼ú µîÀÌ ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹Í°ú ÀçÅñٹ« ½Ã³ª¸®¿À°¡ Áõ°¡ÇÔ¿¡ µû¶ó »çȸÀû °Å¸®µÎ±â ±Ô¹üÀ¸·Î ÀÎÇØ ¹Ý·Áµ¿¹° ÀÔ¾çÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀϺδ ¿ì¿ïÁõ°ú ºÒ¾ÈÁõ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 'À¯·´ ¹Ý·Áµ¿¹°»ç·á »ê¾÷: »ç½Ç°ú ¼öÄ¡ 2022' º¸°í¼­¿¡ µû¸£¸é 2021³â µ¶ÀÏ¿¡¼­ 1,030¸¸ ¸¶¸®ÀÇ °³¿Í 1,670¸¸ ¸¶¸®ÀÇ °í¾çÀÌ°¡ ÀÔ¾çµÈ °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. °°Àº Á¤º¸¿ø¿¡ µû¸£¸é 2021³â µ¶ÀÏ¿¡¼­ °í¾çÀ̸¦ ÇÑ ¸¶¸® ÀÌ»ó ±â¸£´Â °¡Á¤ÀÇ ºñÀ²Àº °³´Â 21%, °í¾çÀÌ´Â 19%¿´´Ù°í ÇÕ´Ï´Ù. ÀÌ´Â °³¿¡ ºñÇØ °í¾çÀÌÀÇ ÀÔ¾ç·üÀÌ Àα¸ Áß °í¾çÀÌÀÇ ÀÔ¾ç·üÀÌ ´õ ³ô´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù.

ƯÈ÷ ¹Ý·Á°ßÀÇ ¾Ï ¹ß»ý·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ±â¹ÝÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¿¹° ¾Ï Àç´Ü¿¡ µû¸£¸é 2022³â ±âÁØ ¹Ì±¹¿¡¼­´Â 6,500¸¸ ¸¶¸®ÀÇ °³¿Í 3,200¸¸ ¸¶¸®ÀÇ °í¾çÀÌ°¡ ¾ÏÀ¸·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ¼öÀÇ»çÇùȸ¿¡ µû¸£¸é °³´Â ¾Ç¼º ½Å»ý¹°(Á¾¾ç)°ú ¸²ÇÁÁ¾¿¡ °É¸®±â ½±½À´Ï´Ù. ÀÌ ½ÃÀåÀº ƯÈ÷ ¾Ï Ä¡·á¿Í °ü·ÃµÈ Á¤ºÎ ¹× ¹Î°£ ´ÜüÀÇ ¼ö¸¹Àº °Ç°­ °ü·Ã ±¸»ó¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¹Ý·Áµ¿¹° ¼ÒÀ¯ÀÚ Áõ°¡·Î ¹Ý·Áµ¿¹°ÀÇ È°µ¿À» ¸ð´ÏÅ͸µÇÏ°í µ¿¹°ÀÇ °Ç°­À» °ü¸®ÇÏ´Â ¿©·¯ ¹Ý·Áµ¿¹° ¸ð´ÏÅ͸µ ¹× ¹Ý·Áµ¿¹° ÃßÀû Á¦Ç°ÀÌ °³¹ßµÇ¾î Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇß½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 1¿ù GPS ±â¹Ý ÃßÀû Àåºñ ȸ»çÀÎ Æ®·¢Æ¼ºê(Tractive)´Â °í¾çÀÌ¿ë LTE GPS ÃßÀû±â¸¦ Ãâ½ÃÇß½À´Ï´Ù. ¶ÇÇÑ 2022³â 6¿ù, Petlibro´Â Granary ½Ã¸®Áî¿¡¼­ »õ·Î¿î 5L Ä«¸Þ¶ó ¸ð´ÏÅ͸µ ÀÚµ¿ ¹Ý·Áµ¿¹° ÇÇ´õ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¹Ý·Áµ¿¹° ¸ð´ÏÅ͸µ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í âÃâÇÏ°í Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª À§Á¶ ÀǾàÇ°ÀÇ »ç¿ë°ú µ¿¹° ½ÇÇè ¹× ¼öÀÇÇÐ ºñ¿ë Áõ°¡´Â ¿¹Ãø ±â°£ Áß ¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀå µ¿Çâ

¹é½Å ºÎ¹®Àº ¿¹Ãø ±â°£ Áß Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»ó

¹é½Å ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀå¿¡¼­ »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Àμö°øÅëÀü¿°º´ ¹× ¸¸¼ºÁúȯ Áõ°¡, Á¦Ç° Ãâ½Ã Áõ°¡, µ¿¹° °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¤ºÎ ±â°ü ¹× ´ÜüÀÇ ÅõÀÚ Áõ°¡, ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

¹é½ÅÀº ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¶Ç´Â ±âŸ Áúº´À» À¯¹ßÇÏ´Â ¹Ì»ý¹°À» Á×À̰ųª º¯Çü½ÃÄÑ Áúº´À» ÀÏÀ¸Å°Áö ¾Ê°í ¸é¿ª·ÂÀ» °­È­ÇÏ´Â °ÍÀ¸·Î ±¸¼ºµË´Ï´Ù. ÀÌ·¯ÇÑ º´¿øü¿¡¼­ À¯·¡ÇÑ À¯ÀüÀÚ º¯Çü ¼ººÐÀ» Æ÷ÇÔÇÏ´Â »õ·Î¿î ÷´Ü ¹é½ÅÀÌ »ý»êµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àü ¼¼°è¿¡¼­ ±¤°ßº´ ȯÀÚ ¼ö°¡ Áõ°¡ÇÏ´Â °ÍÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 5¿ù WHO°¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é °³´Â Àΰ£ ±¤°ßº´ »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î Àüü Àΰ£ ±¤°ßº´ °¨¿°ÀÇ ÃÖ´ë 99.0%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¹é½Å Á¢Á¾Àº ¹Ý·Áµ¿¹°À» Àü¿°º´À¸·ÎºÎÅÍ º¸È£ÇÒ »Ó¸¸ ¾Æ´Ï¶ó µ¿¹°¿¡°Ô ¹°·ÈÀ» ¶§ ÁÖÀÎÀ» º¸È£ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¹Ý·Áµ¿¹°¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ±â¾÷Àº ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ Àü ¼¼°è¿¡¼­ »õ·Î¿î ¹é½ÅÀ» °³¹ß ¹× Ãâ½ÃÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 3¿ù ·¯½Ã¾Æ¿¡¼­ ¼¼°è ÃÖÃÊÀÇ ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º¿¡ ´ëÇÑ µ¿¹°¿ë ¹é½ÅÀÌ µî·ÏµÇ¾úÀ¸¸ç, ÀÌ ¹é½ÅÀº Rosselkhoznadzor(¿¬¹æ ¼öÀǽĹ°°Ë¿ª°¨½Ã±¹)ÀÇ ÀϺΠºÎ¼­¿¡¼­ °³¹ßÇÑ Carnivac-Cov¶ó´Â À̸§À¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. Carnivac-CovÀÇ ÀÓ»ó½ÃÇè¿¡´Â °³, °í¾çÀÌ ¹× ±âŸ µ¿¹°ÀÌ Âü¿©Çß½À´Ï´Ù.

¶ÇÇÑ 2022³â 6¿ù, Àεµ¿¡¼­´Â ¿¬ÇÕ ³ó¾÷ ¹× ³ó¹Î º¹ÁöºÎ Àå°ü Shri Narendra Singh Tomar°¡ ICAR ±¹¸³ ¿¬±¸¼¾ÅÍ°¡ °³¹ßÇÑ µ¿¹° ¹é½Å ¹× ±âŸ Áø´Ü Å°Æ®¸¦ Ãâ½ÃÇß½À´Ï´Ù. ¸»¿ë Ancovax ¹é½ÅÀº µ¿¹°¿ë ºñÈ°¼ºÈ­ SARS-CoV-2 µ¨Å¸(COVID-19) ¹é½ÅÀÔ´Ï´Ù. Ancovax¿¡ ÀÇÇØ À¯µµµÈ ¸é¿ªÀº SARS-CoV-2ÀÇ µ¨Å¸ º¯Á¾°ú ¿À¹ÌÅ©·Ð º¯Á¾À» ¸ðµÎ ÁßÈ­½Ãŵ´Ï´Ù. ÀÌ ¹é½Å¿¡´Â ºñÈ°¼ºÈ­µÈ SARS-CoV-2(µ¨Å¸) Ç׿øÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç º¸Á¶Á¦·Î ¾Ë ÇÏÀ̵å·Î °ÖÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

¶ÇÇÑ 2022³â 9¿ù ¼¼°è ±¤°ßº´ÀÇ ³¯À» ¸Â¾Æ ¸ÓÅ© µ¿¹° °Ç°­(Merck Animal Health)´Â°³ ¸Å°³ ±¤°ßº´ ÅðÄ¡¸¦ Áö¿øÇϱâ À§ÇØ ÀÚ»çÀÇ ±¤°ßº´ ¹é½Å '³ëºñ¹é(NOBIVAC)' ¾à 500¸¸ ȸ ºÐ·®À» ±âºÎÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¸ÓÅ©´Â ¾ÆÇÇ¾Æ ÇÁ·Î±×·¥À» ÅëÇØ ±¤°ßº´ ¹Ì¼Ç, ±¤°ßº´ ¾ø´Â ¾ÆÇÁ¸®Ä« µî ÁÖ¿ä ÆÄÆ®³Ê¿¡°Ô ¹é½ÅÀ» ±âºÎÇÏ°í, ÀÌµé ´Üü´Â Àü ¼¼°è¿¡¼­ Áý´Ü ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎÀ» ÅëÇØ °³¿¡°Ô ¹é½ÅÀ» Á¢Á¾ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº °á±¹ ½ÃÀå ¼ºÀåÀ¸·Î À̾îÁý´Ï´Ù.

µû¶ó¼­ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀåÀÇ Á¶»ç ´ë»ó ºÎ¹®Àº ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì°¡ ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ºñ½ÁÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì´Â ¹Ý·Áµ¿¹° ¼ö¿ë Áõ°¡, ¹Ý·Áµ¿¹° °Ç°­°ü¸® ¹× ÀÌ¿ë °¡´ÉÇÑ ¼­ºñ½º¿¡ ´ëÇÑ ¹Ý·Áµ¿¹° ¼ÒÀ¯ÀÚÀÇ ÀÎ½Ä Áõ°¡, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ¹Ý·Áµ¿¹° °Ç°­°ü¸® ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ý·Áµ¿¹° Àα¸ Áõ°¡¿Í ¹Ý·Áµ¿¹° µ¹º½¿¡ ´ëÇÑ ÁöÃâ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ¹Ý·Áµ¿¹°Á¦Ç°Çùȸ(APPA)°¡ ½Ç½ÃÇÑ 2021-2022³â Àü±¹ ¹Ý·Áµ¿¹° ¼ÒÀ¯ÀÚ Á¶»ç¿¡ µû¸£¸é ¹Ì±¹³» 70%ÀÇ °¡±¸°¡ ¹Ý·Áµ¿¹°À» Å°¿ì°í ÀÖÀ¸¸ç, ÀÌ´Â 9,050¸¸ °¡±¸¿¡ ÇØ´çÇÕ´Ï´Ù. ¶ÇÇÑ APPA¿¡ µû¸£¸é 2019-2020³â±îÁö ¹Ì±¹ÀÇ ¾à 6,900¸¸ °¡±¸°¡ °³¸¦ Å°¿ì°í, 4,530¸¸ °¡±¸°¡ °í¾çÀ̸¦ Å°¿ü´Ù°í ÇÕ´Ï´Ù.

¶ÇÇÑ 2022³â 5¿ù Pet KeenÀÌ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2021³â ij³ª´Ù °¡±¸ÀÇ ¾à 38%°¡ °í¾çÀ̸¦ Å°¿ì°í ÀÖÀ¸¸ç, 35%´Â °³¸¦ Å°¿ì°í ÀÖ½À´Ï´Ù. °°Àº Á¤º¸¿ø¿¡ µû¸£¸é ij³ª´ÙÀÇ ¹Ý·Áµ¿¹° ¼ÒÀ¯ÁÖµéÀº ÀÌÀüº¸´Ù ¹Ý·Áµ¿¹°¿¡ ´õ ¸¹Àº µ·À» ¾²°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ¹Ý·Áµ¿¹° ÁÖÀÎÀÇ 17%´Â ¸Å³â ¹Ý·Áµ¿¹° °Ç°­°ü¸®¸¦ À§ÇØ 500´Þ·¯ ÀÌ»óÀ» ±â²¨ÀÌ ÁöÃâÇÒ ÀÇÇâÀÌ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ¹Ý·Áµ¿¹° °Ç°­°ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó µ¿¹°º° °Ç°­°ü¸®¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¹Ý·Áµ¿¹°ÀÇ ¸¸¼ºÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ý·Áµ¿¹° °Ç°­°ü¸® Á¦Ç° ¹× Áúº´À» °¨ÁöÇÏ°í Ä¡·áÇϱâ À§ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 9¿ù¿¡ ¹ßÇ¥µÈ ±â»ç¿¡ µû¸£¸é Ä¡ÁÖÁúȯÀº ¼öÀÇ»ç Áø·á ÇöÀå¿¡¼­ ÀÚÁÖ ¹ß»ýÇÏ´Â ¹®Á¦ÀÎ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹Ý·Á°ßÀÇ Æò±Õ À¯º´·üÀº 9.3-18.2%¿´Áö¸¸, ¸¶ÃëµÈ ¹Ý·Á°ß¿¡ ´ëÇÑ Á¤¹Ð °Ë»ç¿¡¼­ ÀÌ ÁúȯÀÇ À¯º´·üÀÌ 44-100%·Î ÈξÀ ´õ ³ôÀº °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ¹Ý·Áµ¿¹°¿¡°Ô È¿°úÀûÀÎ Ä¡·áÁ¦¸¦ °³¹ßÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¶ÇÇÑ ±¹³» Ä¡·áÁ¦ ¿¬±¸°³¹ß Áõ°¡¿Í ¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüµµ ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 5¿ù Àç±Ô¾î Çコ(Jaguar Health, Inc.)´Â ¼öÀÇ»ç Ä¿¹Â´ÏƼ¿Í ¼öÀÇ»ç Ä¿¹Â´ÏƼ¸¦ À§ÇÑ ÃÖÃÊÀÇ Àü±¹ÀûÀΰ³ ¾Ï µî·Ï ¹×°³ ¾Ï Ä¡·á Áö¼öÀÎ '°³ ¾Ï: Take CHARGE(Canine Cancer: Take CHARGE(Canine Health And ReGistry Exchange)'¸¦ Ãâ¹üÇß½À´Ï´Ù. ¹Ý·Á°ß º¸È£Àڴ°³ ¾Ï Áø´Ü ¹× Ä¡·á °áÁ¤¿¡ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ ¹ß»ý·ü ¹× À¯º´·ü µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2021³â 11¿ù ¹ÙÀÌ¿¤ ij³ª´Ù°¡ ¹Ý·Á°ß ¿ÜÀÌ¿°¿¡ ´ëÇÑ À¯ÀÏÇÑ 1ȸ Åõ¿© ¼öÀÇ»ç ó¹æ 1Â÷ Ä¡·áÁ¦ÀΠŬ¶ó·Î(Claro)¸¦ Ãâ½ÃÇß½À´Ï´Ù. Ŭ¶ó·Î´Â È¿¸ð±Õ(¸»¶ó¼¼Æ¼¾Æ ÆÄÅ°µ¨¸¶Æ¼½º) ¹× ¼¼±Õ(Ȳ»öÆ÷µµ»ó±¸±Õ)ÀÇ °¨¼ö¼º ±ÕÁÖ¿Í °ü·ÃµÈ ¹Ý·Á°ß ¿ÜÀÌ¿° Ä¡·á¿¡ Ưº°È÷ »ç¿ëµË´Ï´Ù.

µû¶ó¼­ ¾Õ¼­ ¾ð±ÞÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î »ê¾÷ °³¿ä

¹Ý·Áµ¿¹°¿ë ÇコÄÉ¾î ½ÃÀåÀº ÅëÇյǾî ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ °¡Àå Å« Á¡À¯À²Àº ÀÌµé ¼¼°è ±â¾÷ÀÌ Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÇöÀç ÀÌ ½ÃÀå¿¡ ÁøÀÔÇÑ ±â¾÷Àº °ÅÀÇ ¾øÀ¸¸ç, °¡±î¿î ½ÃÀÏ ³»¿¡ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¹Ý·Áµ¿¹° ÀÔ¾çÀÇ Áõ°¡
    • Á¤ºÎ ¹× µ¿¹° º¹Áö ´Üü¿¡ ÀÇÇÑ ±¸»óÀÇ Áõ°¡
    • µ¿¹° ÇコÄɾ¼­ÀÇ Ã·´Ü ±â¼ú
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • À§Á¶ ÀǾàÇ°ÀÇ »ç¿ë
    • µ¿¹° ½ÇÇè°ú ¼öÀÇ·áÀÇ ºñ¿ëÀÇ Áõ°¡
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀïÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç° À¯Çüº°
    • Ä¡·áº°
      • ¹é½Å
      • ±¸ÃæÁ¦
      • Ç×°¨¿°Á¦
      • ÀÇ·á¿ë »ç·á÷°¡Á¦
      • ±âŸ
    • Áø´Üº°
      • ¸é¿ªÁø´Ü °Ë»ç
      • ºÐÀÚÁø´Ü
      • ¿µ»ó Áø´Ü
      • ±âŸ
  • µ¿¹° À¯Çüº°
    • °³
    • °í¾çÀÌ
    • ±âŸ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Elanco Animal Health
    • Boehringer Ingelheim Animal Health
    • Virbac
    • Brilliant Bio Pharma
    • Zoetis Inc.
    • Phibro Animal Health Corporation
    • IDEXX LABORATORIES INC
    • Merck & Co., Inc
    • Norbrook
    • Ceva Sante Animale

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

KSA 24.03.12

The Companion Animal Healthcare Market size is estimated at USD 17.90 billion in 2024, and is expected to reach USD 27.57 billion by 2029, growing at a CAGR of 9.03% during the forecast period (2024-2029).

Companion Animal Healthcare - Market

The outbreak of the COVID-19 pandemic impacted the animal healthcare market by increasing the costs of animal testing and veterinary care. Supply chain disruptions and shortages of veterinary medicines were observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export restrictions, and increased demand for medicine for the treatment of COVID-19. For instance, in July 2020, CDC recommended certain guidelines to veterinary professionals for the treatment of companion animals during the COVID-19 pandemic. However, the increasing investment in research and development activities for launching new and innovative products in the animal healthcare market is driving the market. For instance, in July 2021, Merck Animal Health doubled its animal vaccine production capacity in its Kansas manufacturing facility by USD 100 million. This is expected to help the companion animal healthcare market growth over the forecast period.

Certain factors that are contributing to the market growth are the increase in pet adoption, the rise in the number of initiatives by government and animal welfare, as well as advanced technology in animal healthcare.

With the COVID-19 pandemic and the increasing number of work-from-home scenarios, several people have been diagnosed with depression and anxiety because of the social distancing norms, which have increased the adoption of pet animals. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2022 report, 10,300,000 dogs and 16,700,000 cats were reportedly adopted in Germany in 2021. As per the same source, the percentage of German households owning at least one cat was 21% and one dog was 19% in 2021. This shows that the adoption of cats was higher among the population as compared to dogs.

The rising incidence of cancer, especially in dogs, is anticipated to provide a growth platform for the market. As per the Animal Cancer Foundation, 65 million dogs and 32 million cats are suffering from cancer in the United States as of 2022. Dogs are more prone to suffer from malignant neoplasia (tumor) and lymphoma, as per the American Veterinary Medical Association. The market is supported by numerous health initiatives, especially for cancer treatment, by both government and private organizations.

Furthermore, the growing pet ownership led to the development of some pet monitoring and pet tracking products, that monitor pet activities and take care of animals' health, thereby driving the growth of the studied market. For instance, in January 2022, Tractive, a GPS-based tracking device company launched an LTE GPS tracker for cats. Also, in June 2022, Petlibro launched a new 5L Camera Monitoring Automatic Pet Feeder in its Granary Series. Such developments are expected to further create demand for pet monitoring devices, driving the studied market growth.

However, the use of counterfeit medicines and increasing costs of animal testing and veterinary care are expected to hinder the growth of the companion animal healthcare market over the forecast period.

Companion Animal Healthcare Market Trends

Vaccines Segment is Expected to Grow at a Significant Rate Over the Forecast Period

The vaccines segment is expected to witness significant growth in the companion animal healthcare market over the forecast period owing to factors such as the rising prevalence of zoonotic and chronic diseases, increasing product launches, growing awareness of animal health, rising investments by government bodies and associations, and increasing healthcare expenditure for companion animals.

Vaccines are comprised of viruses, bacteria, or other disease-causing organisms that have been killed or altered so that they cannot cause any disease but can boost immunity. New advanced vaccines have been manufactured containing genetically engineered components derived from those disease agents.

Additionally, the increasing number of cases of rabies across the globe is one of the major factors driving the market's growth over the forecast period. For instance, according to the data published by WHO in May 2021, dogs are the leading cause of human rabies mortality and account for up to 99.0% of all human rabies transmissions. Vaccination is important for companion animals as it not only safeguards them from epidemics but also protects owners in case of any animal bites.

Furthermore, market players are developing and launching new vaccines globally to enhance their market presence, which is also contributing to the segment's growth. For instance, in March 2021, the world's first animal vaccine against the novel coronavirus was registered in Russia, named Carnivac-Cov, which is developed by a unit of Rosselkhoznadzor (Federal Service for Veterinary and Phytosanitary Surveillance). The clinical trials of Carnivac-Cov involved dogs, cats, and other animals.

Also, in June 2022, in India, the Union Minister of Agriculture and farmers' welfare, Shri Narendra Singh Tomar launched animal vaccines and other diagnostic kits developed by the ICAR-National Research Centre on Equines. The Ancovax Vaccine on Equines is an inactivated SARS-CoV-2 Delta (COVID-19) Vaccine for Animals. The immunity induced by Ancovax neutralizes both Delta and Omicron Variants of SARS-CoV-2. The vaccine contains inactivated SARS-CoV-2 (Delta) antigen with Alhydrogel as an adjuvant.

Moreover, in September 2022, Merck Animal Health announced on World Rabies Day that it has donated around five million doses of its NOBIVAC rabies vaccine to help eliminate canine-mediated rabies. Through its Afya Program, Merck donated the vaccines to key partners such as Mission Rabies and Rabies Free Africa, who administer the vaccine to dogs via mass vaccination campaigns across the world. Development such as these ultimately lead to market growth.

Thus, owing to the above-mentioned factors, the studied segment of the companion animal healthcare market is expected to grow significantly over the forecast period.

North America Dominates the Market and Expects to do the Same Over the Forecast Period

North America is expected to dominate the companion animal healthcare market over the forecast period owing to factors such as the rising adoption of companion animals, growing awareness among pet owners about pet healthcare and available services, as well as the presence of key market players in the region.

The growing pet population and an increase in spending on pet care are fueling market growth. For instance, according to the National Pet Owners Survey 2021-2022 conducted by the American Pet Products Association (APPA), 70% of households own a pet in the United States, which equates to 90.5 million homes. In addition, as per APPA, during the 2019-20 period, around 69 million US households owned a dog, and 45.3 million families owned a Cat.

Additionally, the data published by Pet Keen in May 2022 showed that nearly 38% of Canadian households owned a cat while 35% owned a dog in 2021. As per the same source, pet owners in Canada are spending more money on their pets than before, and 17% of owners are willing to spend more than USD 500 every year for their pet's healthcare. This awareness about pet healthcare among pet owners is expected to create demand for products and services available for per-animal healthcare.

Furthermore, the rising number of chronic diseases among pet animals are further creating demand for companion animal healthcare products and diagnostics for disease detection and treatment. For instance, from an article published in September 2021, it has been observed that periodontal disease is a frequent problem seen in veterinary practices; an average prevalence of 9.3 to 18.2% was noticed within the dog population, while the detailed examinations of anesthetized dogs reported a much higher prevalence of the disease, between 44 and 100%. This is expected to create an opportunity for the development of effective therapeutics for pets in the region, thereby propelling the market growth.

Moreover, the increasing research and development for therapeutic products and continuous advancements in technology in companion animal healthcare in the country are other major factors driving the market growth. For instance, in May 2022, Jaguar Health, Inc. launched the Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange), a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index to provide the veterinary community and dog owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions. Also, in November 2021, Bayer Canada launched Claro, the only single-dose, veterinarian-administered first-line treatment for canine otitis externa. Claro is used specifically for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Therefore, owing to the aforesaid factors, the market is expected to witness growth over the forecast period.

Companion Animal Healthcare Industry Overview

The market for companion animal healthcare is consolidated. It is majorly dominated by a few players, such as Elanco, Zoetis Animal Healthcare, Ceva Sante Animale, Merck, Virbac, and Boehringer Ingelheim Animal Health, among others. The largest share of the market is captured by these global players. However, few companies are penetrating the market currently and are expected to hold a substantial share of the market in the near future.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Pet Adoption
    • 4.2.2 Rise in the Number of Initiatives by Governments and Animal Welfare Associations
    • 4.2.3 Advanced Technology in Animal Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Use of Counterfeit Medicines
    • 4.3.2 Increasing Costs of Animal Testing and Veterinary Care
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 By Therapeutics
      • 5.1.1.1 Vaccines
      • 5.1.1.2 Parasiticides
      • 5.1.1.3 Anti-Infectives
      • 5.1.1.4 Medical Feed Additives
      • 5.1.1.5 Other Therapeutics
    • 5.1.2 By Diagnostics
      • 5.1.2.1 Immunodiagnostic Tests
      • 5.1.2.2 Molecular Diagnostics
      • 5.1.2.3 Diagnostic Imaging
      • 5.1.2.4 Other Diagnostics
  • 5.2 By Animal Type
    • 5.2.1 Dogs
    • 5.2.2 Cats
    • 5.2.3 Other Companion Animals
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Elanco Animal Health
    • 6.1.2 Boehringer Ingelheim Animal Health
    • 6.1.3 Virbac
    • 6.1.4 Brilliant Bio Pharma
    • 6.1.5 Zoetis Inc.
    • 6.1.6 Phibro Animal Health Corporation
    • 6.1.7 IDEXX LABORATORIES INC
    • 6.1.8 Merck & Co., Inc
    • 6.1.9 Norbrook
    • 6.1.10 Ceva Sante Animale

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦